Latest Photoacoustic Research Entitled: 'The Effect of Low Frequency Noise Power on Image Quality in Photoacoustic Imaging Systems'

ANN ARBOR, MI / ACCESSWIRE / September 6, 2017 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has been invited to present new photoacoustic imaging research at the 2017 World Molecular Imaging Congress being held on September 13-16, 2017 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

ENDRA Life Sciences Chief Technology Officer Michael Thornton is scheduled to present on Saturday, September 16 at 1:30 p.m. Eastern time in Exhibit Hall A, Poster Session 4.

The poster presentation (P373) entitled, 'The Effect of Low Frequency Noise Power on Image Quality in Photoacoustic Imaging Systems' will demonstrate how increasing low frequencies by only 1.5% can increase the Contrast to Noise Ratio (CNR) by 150% thus enabling researchers to see anatomical detail at new depths. Concurrent with the new research, ENDRA will showcase its latest photoacoustic computed tomography system, the Nexus 128+, with proprietary 3D imaging technology in Booth #334.

"The Nexus 128+ provides up to twice the photoacoustic sensitivity of our previous system, the Nexus 128, enabling improved quantitation of preclinical animal models," said Michael Thornton, ENDRA's Chief Technology Officer. "We are also experiencing positive momentum with our Nexus 128+ in the international marketplace and look forward to announcing new installations with leading research universities in 2017 and beyond."

"ENDRA's continued success with our preclinical photoacoustic CT scanners used by global research scientists underscores our commitment to commercializing leading edge tools, and our plan to bring to market a disruptive technology for the clinical market in 2018," said Francois Michelon, ENDRA's CEO.

About WMIC 2017: IMAGinING the Future Call for Abstracts

The WMIC 2017 will feature more than 200 oral presentations and more than 850 scientific poster presentations from world-renowned institutions from around the globe, with keynote sessions on advances that will refine animal models, accelerate research and improve clinical care. The WMIC Scientific Program Committee is currently accepting abstract submissions in the following emphases: Neuroscience; Oncology; Cardiology; Inflammation and Infectious Diseases; Metabolic Diseases; Instrumentation and Computation; Basic Biology and Bioengineering. For more information about WMIC 2017 click here.

About World Molecular Imaging Society

The WMIS is dedicated to developing and promoting translational research through multimodality molecular imaging. The education and abstract-driven WMIC is the annual meeting of the WMIS and is held in conjunction with partner societies including the European Society for Molecular Imaging (ESMI) and the Federation of Asian Societies for Molecular Imaging (FASMI). WMIC provides a unique setting for scientists and clinicians with very diverse backgrounds to interact, present, and follow cutting-edge advances in the rapidly expanding field of molecular imaging that impacts nearly every biomedical discipline. Industry exhibits at the congress included corporations who have created the latest advances in preclinical and clinical imaging approaches and equipment, providing a complete molecular imaging educational technology showcase. For more information about WMIS:

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models with high image quality and volume scanning speed. ENDRA's next generation Thermo-Acoustic Enhanced UltraSound ("TAEUS") will enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI -- at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally. ENDRA's goal is to bring new capabilities to ultrasound -- thereby broadening access to better healthcare. For more information, please visit

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), which can be found on the SEC's website at We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464

Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235

SOURCE: ENDRA Life Sciences Inc.